Core Viewpoint - Predictive Oncology is advancing its artificial intelligence and machine learning initiatives to enhance early drug discovery and drug development for cancer patients globally, while also implementing a digital asset treasury strategy involving ATH tokens from the Aethir ecosystem [1][14]. Transaction Overview - The company plans to raise approximately $344.4 million through two private investment transactions, which include the sale of about 66.7 million shares at a price of $0.7751 per share, generating around $51.7 million in cash proceeds, and pre-funded warrants for up to 223.6 million shares, valued at approximately $292.7 million in notional value [2]. - The transactions are expected to close around October 2, 2025, pending customary closing conditions [2]. Use of Proceeds - The funds from the private placements will primarily be used to support the digital asset treasury strategy, acquire ATH tokens in the open market, and for general corporate purposes [3]. Aethir Infrastructure - Aethir operates a large decentralized GPU network, providing AI infrastructure with cost savings of approximately 40-80% compared to traditional providers, and offers rapid deployment of services [4]. - The network consists of 435,000 GPU containers across over 200 locations in 93 countries, facilitating global access to Nvidia GPUs-as-a-Service [4]. Digital Asset Strategy - The digital asset treasury will manage ATH tokens, leveraging Aethir's model to enhance the deployment and monetization of compute resources across various enterprise sectors [5]. - For every ATH token purchased, the DCI Foundation will grant an additional 20% of the tokens to the company, linking ATH token value to real-world infrastructure demand [6]. Strategic Partnership - The partnership with Aethir is viewed as a significant opportunity for Predictive Oncology to solidify its core business and explore growth through the digital asset treasury strategy [7]. - The company aims to establish the world's first Strategic Compute Reserve, functioning as an operator within the Aethir ecosystem [8]. Advisory and Legal Support - DNA Holdings Venture, Inc. is acting as the strategic advisor for the digital asset treasury, while H.C. Wainwright & Co. serves as the exclusive placement agent for the private placements [9].

Core Viewpoint - Predictive Oncology Inc. will implement a 1-for-15 reverse stock split to comply with Nasdaq's minimum bid price requirement, effective September 30, 2025 [2][3]. Group 1: Reverse Stock Split Details - The reverse stock split will combine every 15 shares of common stock into one share, resulting in a reduction from 11,436,201 shares outstanding to approximately 762,414 shares [3][4]. - The reverse stock split will not change the par value per share and will affect all stockholders uniformly, with fractional shares being rounded up to the nearest whole share [3][4]. - Stockholders will receive a transaction statement from Pacific Stock Transfer, the exchange agent, detailing their new share count post-split [3][4]. Group 2: Company Overview - Predictive Oncology is focused on AI-driven drug development, utilizing its AI platform, PEDAL, which predicts with 92% accuracy the response of tumor samples to drug compounds [5]. - The company has a biobank of over 150,000 assay-capable heterogeneous human tumor samples, enhancing its drug discovery capabilities [5]. - Predictive Oncology is headquartered in Pittsburgh, PA, and aims to expedite drug development for cancer patients globally [5].

Core Insights - Predictive Oncology Inc. and Every Cure have announced a strategic collaboration aimed at identifying and prioritizing existing drugs for repurposing to enhance patient outcomes and save lives [1][4] - The collaboration leverages AI-driven platforms and extensive biobanks to accelerate drug repurposing efforts, particularly for patients with cancer and other diseases lacking approved treatments [3][8] Group 1: Company Overview - Predictive Oncology is a leader in AI-driven drug development, utilizing machine learning to predict patient responses to anti-cancer therapies [2][8] - The company has a biobank of over 150,000 tumor samples across more than 130 cancer types, which supports its drug discovery and development processes [5][8] - Every Cure is a nonprofit organization focused on repurposing existing drugs to treat diseases, aiming to deliver treatments quickly and cost-effectively [3][6] Group 2: Collaboration Details - The partnership aims to combine the AI capabilities of both organizations to overcome barriers in drug repurposing and improve healthcare accessibility [4][5] - Every Cure's AI models utilize knowledge graphs and real-world medical data to identify potential drug-disease connections, which are then evaluated for safety and efficacy [5] - Predictive Oncology's platform has demonstrated a 92% accuracy in predicting tumor responses to drugs, enhancing the selection process for drug testing [8]

Group 1 - The proposed sale of Predictive Oncology Inc. to Renovaro Inc. involves a merger where Predictive Oncology shareholders will receive a newly created series of preferred stock in a 1:1 exchange for their existing common stock [1] - Kahn Swick & Foti, LLC is investigating whether the terms of the proposed sale adequately reflect the value of Predictive Oncology and the process leading to this transaction [1] - The investigation is led by former Louisiana Attorney General Charles C. Foti, Jr., indicating a legal scrutiny of the transaction [1][2] Group 2 - Kahn Swick & Foti, LLC is open to discussions regarding the legal rights of shareholders who believe the transaction undervalues Predictive Oncology [2] - Shareholders can contact KSF Managing Partner Lewis S. Kahn for more information about their rights related to the proposed sale [2]

Financial Performance - The company reported a loss from continuing operations of approximately $2.0 million for Q2 2025, compared to a loss of $2.5 million in Q2 2024[1][10]. - Revenue for Q2 2025 was $2,682, a significant decrease from $67,255 in Q2 2024, primarily due to decreased sales of tumor-specific 3D models and kits[8][11]. - Basic and diluted loss per common share from continuing operations was $0.22 for Q2 2025, down from $0.53 in Q2 2024[8][11]. - Total stockholders' deficit increased to $1,653,400 as of June 30, 2025, compared to a deficit of $202,610 as of December 31, 2024[8][9]. Cash and Expenses - The company ended Q2 2025 with $506,078 in cash and cash equivalents, down from $611,822 as of December 31, 2024[8][9]. - General and administrative expenses increased by $50,481 to $1,875,655 in Q2 2025, compared to $1,825,174 in Q2 2024[8][11]. Market Expansion and Product Development - The company is preparing for an aggressive market expansion of its ChemoFx assay in the U.S. and a de novo launch in Europe, both anticipated in Q4 2025[3][4]. - The company has developed two unique 3D liver toxicity models for Labcorp, which can evaluate drug metabolism and liver toxicity[4]. - The company identified three promising candidates for repurposing from abandoned drugs, specifically Afuresertib, Alisertib, and Entinosta, for colon and breast tumor indications[4]. Financing Activities - A standby equity purchase agreement for up to $10 million was announced with YA II PN, LTD, managed by Yorkville Advisors Global, LP[4].

Core Viewpoint - Predictive Oncology reported a loss from continuing operations of approximately $2.0 million for Q2 2025, while focusing on advancing its AI-driven drug discovery and expanding its ChemoFx assay in the U.S. and Europe [1][3]. Financial Summary - The company concluded Q2 2025 with cash and cash equivalents of $506,078, down from $611,822 as of December 31, 2024 [4]. - Revenue for Q2 2025 was $2,682, a significant decrease from $67,255 in Q2 2024, primarily due to reduced sales of tumor-specific 3D models and kits [10]. - General and administrative expenses increased to $1,875,655 in Q2 2025 from $1,825,174 in Q2 2024, mainly due to higher legal fees [10]. - The company raised approximately $586,000 in gross proceeds during the quarter through private placements and its At-the-Market facility [6]. Operational Highlights - The company is preparing for an aggressive market expansion of its ChemoFx assay in the U.S. and a de novo launch in Europe, both expected in Q4 2025 [5]. - ChemoFx helps oncologists make better treatment decisions by testing multiple chemotherapies on patients' cancer cells before treatment selection [5]. - Predictive Oncology has developed two unique 3D liver toxicity models for Labcorp, which can evaluate drug metabolism and liver toxicity [5]. - The company identified three promising candidates for repurposing from abandoned drugs, specifically Afuresertib, Alisertib, and Entinosta, for colon and breast tumor indications [5]. Capital and Investment - A standby equity purchase agreement for up to $10 million was announced with YA II PN, LTD, managed by Yorkville Advisors Global, LP, providing a flexible source of capital for advancing initiatives [5].

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________________ to _________________________ Commission File Number: 001-36790 Predictive Oncology Inc. (Exact name of registrant as specified in its ...

Core Insights - Predictive Oncology Inc. has announced a $10 million Securities Purchase Agreement to support its strategic growth initiatives, particularly the expansion of ChemoFx in the U.S. and its launch in Europe [1][13][14] - ChemoFx is a proprietary live-cell tumor profiling assay that provides personalized chemotherapy guidance by testing multiple chemotherapies on a patient's cancer cells [2][3] - The company has a biobank of over 150,000 tumor samples, which enhances its drug response data and supports recurring revenue opportunities [3][9] ChemoFx Expansion - The groundwork for expanding ChemoFx in the U.S. is underway, with discussions ongoing with potential channel partners and pharmaceutical manufacturers [3] - Future developments of ChemoFx are expected to extend beyond gynecological cancers to include breast, colon, and lung cancers [4] High-Throughput Screening Market - The high-throughput screening market is projected to reach $69.5 billion by 2032, with a compound annual growth rate (CAGR) of 12.18%, indicating a growing adoption of 3D cell cultures for more relevant screening models [6] AI-Driven Drug Discovery - The company is advancing its AI-driven drug discovery initiatives, which include biomarker discovery and drug repurposing, leveraging its extensive biobank [8][9] - Successful collaborations, such as with UPMC Magee-Womens Hospital, have led to the development of AI-powered models that predict survival outcomes in ovarian cancer patients [10][11] Drug Repurposing Initiatives - The company has identified three drug candidates for re-evaluation in ovarian and colon cancer through active machine learning, showcasing its potential in transitioning shelved drug candidates back into clinical development [12] Funding and Financial Strategy - The Securities Purchase Agreement with Yorkville Advisors provides an efficient and flexible funding source, allowing the company to opportunistically sell shares when market conditions are favorable [13][14] - The company views this agreement as a partnership that will support its vision and growth strategy [14] Company Overview - Predictive Oncology is at the forefront of using AI and machine learning to expedite drug discovery, with a platform that predicts tumor responses with 92% accuracy [16]

Core Insights - Predictive Oncology Inc. has entered into a standby equity purchase agreement (SEPA) with YA II PN, LTD, managed by Yorkville Advisors Global, LP, to secure funding for its drug discovery initiatives [1][2] - The SEPA allows Predictive Oncology to sell up to $10 million worth of its stock at its discretion, with no minimum commitments or penalties for non-use [2] - The company leverages its AI-driven platform, PEDAL, which predicts drug response with 92% accuracy, enhancing drug discovery for cancer treatment [4] Funding Agreement - The SEPA provides Predictive Oncology with a flexible funding source to support ongoing drug discovery, biomarker discovery, and drug repurposing efforts [1] - Yorkville is obligated to purchase the stock, but Predictive Oncology controls the timing and amount of sales [2] - There are no associated warrants, derivatives, or other share classes with the SEPA, and it does not restrict the company's operational activities [2] Company Overview - Predictive Oncology specializes in AI and machine learning applications in drug discovery, aiming to expedite the development of cancer treatments [4] - The company has a biobank of over 150,000 tumor samples, enhancing its drug discovery capabilities [4] - Predictive Oncology is headquartered in Pittsburgh, PA, and offers one of the industry's broadest AI-based drug discovery solutions [4]

Core Insights - Predictive Oncology Inc. has developed 3D organoid models for Labcorp to enhance drug discovery and preclinical analysis of cancer therapies [1][2][3] - The new models include human and rat liver toxicity models that simulate the liver microenvironment for evaluating drug metabolism and toxicity [2][3] - These organoid models aim to predict in vivo drug clearance, transport, and hepatotoxicity, providing species-specific data that captures hepatic cellular heterogeneity [3][4] Company Developments - The 3D organoid models complement Predictive Oncology's existing AI-driven 2D platform and 3D spheroids, which utilize a biobank of over 150,000 frozen tumor samples [3][6] - The company’s AI platform, PEDAL, predicts with 92% accuracy whether a tumor sample will respond to specific drug compounds, aiding in informed drug selection [6] Industry Trends - The use of organoid-based platforms is seen as a key driver in transforming healthcare, accelerating drug development, and reducing reliance on animal models [4] - There is a growing investment in personalized medicine and biotechnology, with organoids offering cost-effective and high-fidelity alternatives to traditional research methods [4]